cancer risk associated with insulin glargine among adult type 2 diabetes patients – a nationwide cohort study癌症风险与成人2型糖尿病患者胰岛素u2014u2014一个全国性的队列研究.pdfVIP

Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study 1,2 3 4 1 5 Chia-Hsuin Chang , Sengwee Toh , Jou-Wei Lin , Shu-Ting Chen , Chuei-Wen Kuo , Lee-Ming 1,2 1 Chuang *, Mei-Shu Lai * 1 Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, 2 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 3 Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States of America, 4 Cardiovascular Center, National Taiwan University Hospital Yun-Lin Branch, Dou-Liou City, Yun-Lin, Taiwan, 5 National Health Insurance Mediation Committee, Department of Health, Executive Yuan, Taipei, Taiwan Abstract Background: Preclinical and observational studies raise the concern about the safety of insulin glargine in terms of cancer initiation and promotion. This study is designed to examine cancer incidence associated with use of insulin glargine vs. intermediate/long-acting human insulin (HI). Methodology: A retrospective cohort study using the Taiwan National Health Insurance claims database was conducted to identify adult patients with type 2 diabetes mellitus and without a history of cancer who initiated insulin glargine (n = 10,190) or intermediate/long-acting HI (n = 49,253) during 2004–2007. Exclusive users were followed from the date of insulin initiation to the earliest of cancer diagnosis, death, disenrollment, or December 31 2007. We estimated adjusted hazard ratios and 95% confidence intervals (CIs) with Cox proportional hazards models adjusting for baseline propensity